JP2024511449A5 - - Google Patents

Info

Publication number
JP2024511449A5
JP2024511449A5 JP2023558496A JP2023558496A JP2024511449A5 JP 2024511449 A5 JP2024511449 A5 JP 2024511449A5 JP 2023558496 A JP2023558496 A JP 2023558496A JP 2023558496 A JP2023558496 A JP 2023558496A JP 2024511449 A5 JP2024511449 A5 JP 2024511449A5
Authority
JP
Japan
Prior art keywords
amino acid
disease
ion channel
channel blocker
side chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511449A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/057533 external-priority patent/WO2022200374A1/en
Publication of JP2024511449A publication Critical patent/JP2024511449A/ja
Publication of JP2024511449A5 publication Critical patent/JP2024511449A5/ja
Pending legal-status Critical Current

Links

JP2023558496A 2021-03-23 2022-03-22 Ｋｖ１．３遮断薬 Pending JP2024511449A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21164384 2021-03-23
EP21164384.6 2021-03-23
EP21213431 2021-12-09
EP21213431.6 2021-12-09
PCT/EP2022/057533 WO2022200374A1 (en) 2021-03-23 2022-03-22 Kv1.3 blockers

Publications (2)

Publication Number Publication Date
JP2024511449A JP2024511449A (ja) 2024-03-13
JP2024511449A5 true JP2024511449A5 (enExample) 2025-03-27

Family

ID=80952156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558496A Pending JP2024511449A (ja) 2021-03-23 2022-03-22 Ｋｖ１．３遮断薬

Country Status (12)

Country Link
US (1) US20240182531A1 (enExample)
EP (1) EP4314024A1 (enExample)
JP (1) JP2024511449A (enExample)
KR (1) KR20230159403A (enExample)
AU (1) AU2022245193A1 (enExample)
BR (1) BR112023019022A2 (enExample)
CA (1) CA3208713A1 (enExample)
CL (1) CL2023002590A1 (enExample)
IL (1) IL305219A (enExample)
MX (1) MX2023010930A (enExample)
TW (1) TW202304957A (enExample)
WO (1) WO2022200374A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4604984A1 (en) * 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
EP2474316B1 (en) 2004-10-07 2016-04-06 The Regents of The University of California Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
NZ709913A (en) 2013-01-25 2019-05-31 Janssen Biotech Inc Kv1.3 antagonists and methods of use
JP2016527250A (ja) 2013-07-22 2016-09-08 キネタ ワン リミテッド ライアビリティ カンパニーＫｉｎｅｔａ Ｏｎｅ，Ｌｌｃ 毒素系治療用ペプチド及びその医薬組成物の眼科的使用
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
EP4031162A1 (en) * 2019-09-20 2022-07-27 Zealand Pharma A/S Kv1.3 blockers

Similar Documents

Publication Publication Date Title
KR102720958B1 (ko) 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물
NZ590466A (en) Treatment of inflammatory diseases with mammal beta defensins
CN100496493C (zh) 2-氨基-4,5-三取代噻唑基衍生物
HRP20210252T1 (hr) Heterociklički amidi kao inhibitori kinaze
WO2000012497B1 (en) Quinazoline derivatives as medicaments
JP2014516945A5 (enExample)
EA035973B9 (en) Amino acid sequences directed against il-17a, il-17f and/or il-17a/f and polypeptides comprising the same
CN104903301B (zh) 可用于调节IL‑12、IL‑23和/或IFNα的烷基酰胺取代的嘧啶化合物
CN101215655B (zh) 亚稳β型Ti-Nb-Ta-Zr-O合金及其制备方法
MX2010001400A (es) Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas.
RU2008137941A (ru) ПРОИЗВОДНЫЕ ОКТАГИДРОПИРРОЛО[3,4-b]ПИРРОЛА (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ ОКТАГИДРОПИРРОЛО[3,4-b]ПИРРОЛА (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ СОСТОЯНИЯ ОРГАНИЗМА, ЧУВСТВИТЕЛЬНОГО К МОДУЛЯЦИИ АКТИВНОСТИ РЕЦЕПТОРА ГИСТАМИНА-3
TW200908969A (en) Organic compounds
RU2016140572A (ru) Конъюгаты антитело-финомер
JP2009534401A5 (enExample)
JP2010535215A5 (enExample)
CA2671982A1 (en) Methods of using mek inhibitors
RU2013145299A (ru) Тиазолопиримидины
WO2008000469A3 (en) Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom
JP2021527031A5 (enExample)
WO2014147586A1 (en) 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
IL274809B1 (en) Antibodies against CXCR5 and compositions and uses thereof
BRPI0607750A2 (pt) composições de matéria, e farmacêutica, dna, vetor de expressão, célula hospedeira, e, uso de uma composição de matéria
JP2011518857A5 (enExample)
RS53521B1 (sr) Priprema i terapijske primene (2s,3r)-n-2-((3-piridinil)metil)-1-azabiciklo[2.2.2]okt-3-il)-3,5-difluorobenzamida
WO2012114268A1 (en) Benzamide derivatives as p2x7 receptor antagonists